Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of loganin to preparation of drugs or health products for preventing and treating mental disturbance diseases such as depressive disorder and anxiety disorder

A technology of mental disorders and loganin, which is applied in the field of medicine, can solve problems such as no research has been seen, and achieve the effects of broadening the scope, wide sources, and good application and development prospects

Inactive Publication Date: 2016-12-07
CHINA JAPAN FRIENDSHIP HOSPITAL
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there has not been any research on the pharmacological effects and clinical applications of loganin in the prevention, alleviation or treatment of depression, anxiety and other mental disorders.
[0007] At present, the Chinese invention patents related to loganin can only be seen in the preparation method (CN104447910A), content determination method (CN103808811A) and the preparation of drugs for treating diabetes (CN103110651A), and there are no reports on mental disorders such as depression and anxiety.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of loganin to preparation of drugs or health products for preventing and treating mental disturbance diseases such as depressive disorder and anxiety disorder
  • Application of loganin to preparation of drugs or health products for preventing and treating mental disturbance diseases such as depressive disorder and anxiety disorder
  • Application of loganin to preparation of drugs or health products for preventing and treating mental disturbance diseases such as depressive disorder and anxiety disorder

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 Effect of loganin on autonomic activity of normal mice

[0030] In this experiment, 20-24g male ICR mice were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. (animal certificate number: SCXK (Beijing) 2012-0001). The breeding temperature was 23±2°C, and the lighting time was 12 mice per day (turn on the lights from 7:00 to 19:00). Experiments were carried out after one week of feeding. The mice were randomly divided into 4 groups according to body weight, 10 in each group, respectively blank control group (distilled water), low-dose loganin group (5mg / kg), medium-dose loganin group (20mg / kg) and loganin Qiangside high-dose group (50mg / kg). The tested drugs were all dissolved in distilled water at 10ml / kg body weight before the experiment, and administered by intragastric administration. Immediately after administration, the mice were put into the mouse autonomic activity recorder, and the locomotor counts of the mice were recor...

Embodiment 2

[0032] Example 2 Effect of loganin on behavior of mice forced swimming test

[0033] For the stress load test, male ICR mice with a body weight of 20-24 g were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. (animal certificate number: SCXK (Beijing) 2012-0001). The breeding temperature is 23±2°C, and the lighting time is 12 hours / day (turn on the lights from 7:00 to 19:00). Experiments were carried out after one week of feeding. This experiment is divided into three days, and the first and second days are training days. Be about to add water in the swimming box to the center of the pulley, about 18cm in height, this water level can ensure that the mice will not climb out of the box by means of the pulley when swimming, and will not be too tired because they cannot reach the pulley. The water temperature is kept at 22-23°C. During the training, put the mouse into the water facing the pulley gently, make it swim for 10 minutes, take it out, dry ...

Embodiment 3

[0038] Example 3 Effect of loganin on the behavior of mice tail suspension experiment

[0039]The mice were randomly divided into 4 groups, and the grouping was the same as above. After 1 hour of intragastric administration, the tail of the mice was glued to the line with adhesive tape at a distance of 2 cm from the end, and connected to the muscle tension transducer to make it hang upside down. The instrument is connected to a desktop balance recorder and placed in a box with its head about 5 cm from the bottom of the box. The hanging time is 6cm, and the immobility time within 4min after accumulation.

[0040] The experimental results are shown in Table 2. In the tail suspension experiment, when 20mg / kg and 50mg / kg loganin were given by intragastric administration, the immobility time of mice could be significantly reduced, and the immobility time of mice could be significantly reduced under the two doses. Compared with the blank control group, there were significant statis...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of compound drugs, and relates to new drug application of loganin, particularly application of loganin to the preparation of drugs or health products for preventing and treating mental disturbance diseases such as depressive disorder and anxiety disorder. The loganin provided by the invention is one of main chemical components of Cornus officinalis which is a Cornaceae plant, the chemical formula of the loganin is C17H26O10, and the molecular weight of the loganin is 390.38; animal experiments prove that the loganin can reduce autonomous exercise intensity of a mouse, the number of rotational turns of a pulley poked by fore limbs of the mouse is obviously increased, the dead time of tail suspension of the mouse is shortened, and an antidepressant effect is shown; the loganin can further increase the time percentage of staying at the open arms of a maze of a stress rat and seek the frequency of arm opening, meanwhile, in a light and shade box shuttling experiment, the loganin can obviously increase the time that the mouse stays in a light box and the frequency of shuttling in the light box, and an obvious anxiolytic effect is shown. Above all, the loganin can be prepared into the drugs or health products for preventing and treating the mental disturbance diseases such as depressive disorder and anxiety disorder, and prepared dosage forms comprise granules, tablets, capsules, granules, powder, oral liquids, dropping pills, pellets or injections.

Description

technical field [0001] The invention belongs to the field of medicaments, and relates to a new drug application of loganin, in particular to the application of loganin in the preparation of drugs or health care products for preventing and treating depression, anxiety and other mental disorders. technical background [0002] Mental disorders, also known as mental illnesses, refer to abnormalities in perception, thinking, emotion, behavior, volition, intelligence, and other psychomotor aspects caused by brain dysfunction under the influence of biological, social, and psychological factors. With the development of society, people pay more and more attention to mental disorders. [0003] Anxiety, depression, etc. are common types of mental disorders, and their incidence rate is very high. At present, they have become the second most important diseases that cause serious burdens on human beings, causing pain to patients and their families, and losses to society. It is unmatched ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K9/20A61P25/24A61P25/22
CPCA61K9/08A61K9/1652A61K9/2054A61K9/4866A61K31/7048
Inventor 张维库续洁琨赫军乔灏祎叶贤胜
Owner CHINA JAPAN FRIENDSHIP HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com